OncoMatch/Clinical Trials/NCT07148128
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Is NCT07148128 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies WEF-001 for advanced or metastatic kras-mutant tumor in pancreatic adenocarcinoma.
Treatment: WEF-001 — This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
Disease stage
Metastatic disease required
Advanced KRAS-mutant solid tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard of care therapy
Progressive disease following at least one line of standard of care therapy
Lab requirements
Liver function
Liver dysfunction [excluded]
Cardiac function
Active cardiovascular disease [excluded]
Liver dysfunction; Active cardiovascular disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NEXT Oncology Dallas · Dallas, Texas
- Next Oncology, San Antonio · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07148128 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard of care therapy.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify